Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04311866 | Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants | N/A | withdrawn | Mar 17, 2020 | Universidad Autonoma de Nuevo Leon | Lack of material for treatment of the patients | Other (stated, no rule matched) |
| NCT05209308 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL(CORAL) | Phase 2 | withdrawn | Jan 26, 2022 | MEI Pharma, Inc. | Discontinuation of zandelisib development | Other (stated, no rule matched) |
| NCT02484261 | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem… | Phase 1 | terminated | Jun 29, 2015 | Reuven Schore | Contractual/Funding/Accrual | Enrollment / accrual |
| NCT02863458 | DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies… | — | withdrawn | Aug 11, 2016 | The Cleveland Clinic | Study was a data review, no patient recruitment occurred. | Enrollment / accrual |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | Phase 1 | terminated | Mar 18, 2019 | Weill Medical College of Cornell University | Dose limiting toxicities. | Safety / toxicity |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or… | Phase 2 | withdrawn | Nov 7, 2019 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT04748848 | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With… | Phase 1 | terminated | Feb 10, 2021 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT04530695 | Diagnosis and Treatment of Periodontal Disease in Patients With AML | N/A | withdrawn | Aug 28, 2020 | Masonic Cancer Center, University of Minnesota | PI left institution and research was cancelled due to his departure | Investigator |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Phase 3 | terminated | Mar 30, 2020 | Goethe University | Change of marketing authorisation holder | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT02543749 | DC Vaccination in CML | Phase 1 / Phase 2 | terminated | Sep 7, 2015 | Charite University, Berlin, Germany | not stated | Not stated |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and… | Phase 1 | terminated | Feb 4, 2022 | Magenta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05362331 | Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy | N/A | withdrawn | May 5, 2022 | University of California, San Francisco | Contract issues | Other (stated, no rule matched) |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute… | Phase 1 / Phase 2 | terminated | Dec 23, 2014 | Calithera Biosciences, Inc | Business Decision; No Safety or Efficacy Concerns. | Safety / toxicity |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT00003407 | Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | Phase 2 | withdrawn | Apr 27, 2004 | Rush University Medical Center | The P.I deceased. | Other (stated, no rule matched) |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young… | Phase 2 | terminated | Jan 13, 2020 | Novartis Pharmaceuticals | Terminated due to slow enrollment | Enrollment / accrual |
| NCT00573378 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | Phase 2 | terminated | Dec 14, 2007 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | Phase 1 / Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell… | Investigator |
| NCT01005914 | Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute… | Phase 2 | terminated | Nov 2, 2009 | OHSU Knight Cancer Institute | Increased rate of bacterial infections | Other (stated, no rule matched) |
| NCT01339910 | Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or… | Phase 3 | terminated | Apr 21, 2011 | Medical College of Wisconsin | Accrual terminated as recommended by the data and safety monitoring board. | Safety / toxicity |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | Phase 1 | terminated | Apr 24, 2009 | Eli Lilly and Company | Lack of efficacy | Efficacy / futility |
| NCT04136665 | Physical Activity Adapted at Home Supervised by Videoconferencing in Post-cancer for… | N/A | terminated | Oct 23, 2019 | University Hospital, Montpellier | Not enough patient | Other (stated, no rule matched) |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | Phase 1 | withdrawn | Dec 23, 2021 | Novartis Pharmaceuticals | Sponsor's decision | Sponsor / business decision |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT01138579 | Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell…(STP-LYM-01) | Phase 1 / Phase 2 | withdrawn | Jun 7, 2010 | Technical University of Munich | Recruitment delayed, trial medication no loner available | Enrollment / accrual |
| NCT04343027 | Patient Satisfaction in the Orthopedic Surgery Clinic | N/A | withdrawn | Apr 13, 2020 | NYU Langone Health | Withdrawn project - did not progress to enrollment. | Enrollment / accrual |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | Phase 1 | terminated | May 27, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic… | Phase 1 / Phase 2 | withdrawn | Oct 6, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Phase 1 / Phase 2 | terminated | Jul 11, 2017 | GT Biopharma, Inc. | Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE… | Other (stated, no rule matched) |
| NCT05611086 | N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia | Phase 4 | terminated | Nov 9, 2022 | Teny Tjitra Sari | The study stopped because the study period already ended | Other (stated, no rule matched) |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia… | Phase 2 | terminated | May 8, 2018 | M.D. Anderson Cancer Center | Due to Competing Studies | Other (stated, no rule matched) |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02448095 | Retrospective Evaluation of CML Patients in the National Compassionate Program | — | terminated | May 19, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT03410407 | Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)(AML1617) | — | terminated | Jan 25, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT04655261 | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection…(FIRST) | — | terminated | Dec 7, 2020 | AbbVie | Lack of Recruitment | Enrollment / accrual |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT01570465 | Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients(AML1411) | — | terminated | Apr 4, 2012 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low interest | Other (stated, no rule matched) |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | Phase 1 | terminated | Aug 4, 2020 | Insel Gruppe AG, University Hospital Bern | Insufficient recruitment | Enrollment / accrual |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | May 4, 2018 | AvenCell Europe GmbH | The actions and measures to be taken to restart the trial could not be implemented which made the… | Other (stated, no rule matched) |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 24, 2023source: clinicaltrials